Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

BACKGROUND: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the form of gross DNA copy number aberrations. Cancers without BRCA1 or BRCA2 loss b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomark Res
Main Authors: Marquard, Andrea M, Eklund, Aron C, Joshi, Tejal, Krzystanek, Marcin, Favero, Francesco, Wang, Zhigang C, Richardson, Andrea L, Silver, Daniel P, Szallasi, Zoltan, Birkbak, Nicolai J
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4443545/
https://ncbi.nlm.nih.gov/pubmed/26015868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-015-0033-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados